December 27, 2022 4:39pm

Tax loss selling, portfolio rebalancing, and investors deciding where and what to position in their portfolios in 2023 with recession possibilities looming

Why do I keep writing this blog/newsletter; to educate and inform investors, what others won’t say or write

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that investors are safer on the sidelines as again … earnings are coming.


Your portfolio should be profiting from RMi’s analysis; subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.


The Dow closed UP +37.63 points (+0.11%), the S&P closed DOWN -15.57 points (-0.40%) while the Nasdaq closed DOWN -144.64 points (-1.38%)



We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Markets were closed Monday for the Christmas holiday. In this shortened trading week, investors are expecting either relative quiet or further volatility due to low trading volumes. <CNBC>

Indexes were mixed as bond yields also pushed higher, putting pressure on growth stocks like technology.

For December, the S&P has dropped 6.2%, while the Dow dived -3.9% and Nasdaq tumbled 9.7%.

So far in 2022, indexes are headed for their worst yearly performance since 2008 with another down month; the Dow is down -8.5%, the S&P -19.7% as the Nasdaq has fallen -33.8%.

Economic Data Docket: S&P Case-Shiller index tracking the U.S. housing market: year over year, the index was up 9.2% in October, coming in below expectations of a 10.4% increase. Home prices fell 0.5% over September.


Tuesday’s … RegMed Investor’s (RMi) Pre-Open: “roaming and ranging, not today. If investors haven’t reduced risk by now, you’re late.” …


RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – quite a difference …

  • Tuesday’s advance/decline line opened negative at 4 up/ 29 down and 2 flats, stayed negative with 2 up/ 31 down and 2 flats at the mid-day, ending with a negative close of 1/33 and 1 flat.
  • Monday was a market holiday


Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was down -2.09% and the XBI was down -2.89%
  • Monday – a market holiday 

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.91. points or +4.36% at 21.78
  • Monday – a market holiday


Closing Down (10 of 33):

  • Alnylam Pharmaceuticals (ALNY -$5.59 after Monday’s holiday and Friday’s -$1.59),
  • CRISPR Therapeutics (CRSP -$3.08 after Monday’s holiday and Friday’s -$1.99),
  • Beam Therapeutics (BEAM -$2.28 after Monday’s holiday and Friday’s -$1.60),
  • Intellia Therapeutics (NTLA -$1.77 after Monday’s holiday and Friday’s -$1.09),
  • Ionis Pharmaceuticals (IONS -$1.00),
  • Sage Therapeutics (SAGE -$0.92 after Monday’s holiday and Friday’s -$1.55),
  • Fate Therapeutics (FATE -$0.81 after Monday’s holiday and Friday’s -$0.65),
  • Chinook Therapeutics (KDNY -$0.76 after Monday’s holiday and Friday’s -$0.86),
  • uniQure NV (QURE -$0.69),
  • Ultragenyx (RARE -$0.65 after Monday’s holiday and Friday’s -$1.28),


  • Biostage (OTCQB: BSTG),

Closing Up (1 of 1):

  • Prime Medicine (PRME +$0.30 after Monday’s holiday and Friday’s +$1.00)


Q4 – December

  • Tuesday closed negative with 1 incliner, 33 decliners and 1 flat
  • Monday was a market holiday


The BOTTOM LINE: I try to keep it simple … and short!

There are clear losers today as Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA) and Ionis Pharmaceuticals (IONS -$1.00) fell to the wayside.

Be prepared … just 3 trading days remain in 2022.

The biggest issue for the New Year will be the cloud of recession overhanging the economy, market volatility that affects and effects our universe of cell and gene therapy sector equities

Avrobio (AVRO closed down again -$0.0341 with 151,542 shares traded after Monday’s holiday and Friday’s-$0.0247 with 128,956 shares traded after Thursday’s -$0.0068 with 121,246 shares traded, Wednesday’s +$0.0001 with 607,023 shares traded, Tuesday’s +$0.0295 with 361,951 shares traded

Says a lot of addressing the delisting issue) having filed a S-3 for $250 million common stock, preferred stock, debt securities, warrants and unit offering within draft prospectus by Cowen as stock sinks while delisting continues?

Just another “screw-job” of investors! < Read, SELL and Weep - see hyperlink below>

Avrobio (AVRO) files S-3 (Registration Statement) for offering with draft prospectus by Cowen …

·         Also, RA Capital has sold its position in the company – a sign of dissatisfaction!

·         While, President, CEO and director Geoff Mackay carries home a HUGE salary of $754.39 K per year?

Biostage (OTCQB: BSTG) closed flat with 117 shares traded on Tuesday after Monday’s holiday after Friday’s $0.00 with 25 shares traded with news of a patent (going nowhere) after Thursday’s $0.00 with 50 shares traded <3-month average =1,928 shares> after Wednesday’s -$0.02 with 624 shares traded, and last Tuesday’s $0.00 with 34 shares traded.

 â€śThe real question that should be asked is how many companies are at the end of sentiments …  leash?


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.